Scott Cramer
Concepts (432)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 39 | 2025 | 974 | 3.980 |
Why?
| | MAP Kinase Kinase Kinases | 8 | 2021 | 70 | 2.270 |
Why?
| | Prostate | 11 | 2014 | 158 | 1.810 |
Why?
| | Receptors, Androgen | 8 | 2021 | 153 | 1.140 |
Why?
| | DNA Helicases | 4 | 2021 | 143 | 1.120 |
Why?
| | Prostate-Specific Antigen | 9 | 2013 | 161 | 0.950 |
Why?
| | Hyperoxaluria, Primary | 5 | 2009 | 14 | 0.890 |
Why?
| | Epithelial Cells | 10 | 2016 | 1125 | 0.850 |
Why?
| | Calcitriol | 6 | 2011 | 58 | 0.840 |
Why?
| | Vitamin D | 4 | 2013 | 400 | 0.840 |
Why?
| | DNA-Binding Proteins | 5 | 2021 | 1499 | 0.780 |
Why?
| | Alcohol Oxidoreductases | 7 | 2011 | 62 | 0.770 |
Why?
| | Interleukin-1alpha | 2 | 2013 | 57 | 0.730 |
Why?
| | Stromal Cells | 2 | 2014 | 124 | 0.610 |
Why?
| | RNA Interference | 2 | 2021 | 476 | 0.610 |
Why?
| | Homologous Recombination | 1 | 2019 | 36 | 0.590 |
Why?
| | Androgens | 4 | 2021 | 186 | 0.560 |
Why?
| | Stem Cells | 3 | 2011 | 626 | 0.500 |
Why?
| | DNA Damage | 1 | 2019 | 430 | 0.480 |
Why?
| | Receptors, Calcitriol | 5 | 2015 | 55 | 0.480 |
Why?
| | Cell Line, Tumor | 17 | 2021 | 3540 | 0.480 |
Why?
| | Cell Division | 9 | 2011 | 766 | 0.470 |
Why?
| | Tumor Suppressor Proteins | 2 | 2012 | 321 | 0.460 |
Why?
| | Epoxy Compounds | 2 | 2015 | 32 | 0.450 |
Why?
| | Carnitine O-Palmitoyltransferase | 2 | 2015 | 49 | 0.450 |
Why?
| | Autophagy | 5 | 2020 | 286 | 0.440 |
Why?
| | Genomic Instability | 1 | 2015 | 66 | 0.440 |
Why?
| | Anticarcinogenic Agents | 2 | 2014 | 61 | 0.430 |
Why?
| | Lactones | 1 | 2014 | 58 | 0.410 |
Why?
| | Breast | 2 | 2014 | 158 | 0.410 |
Why?
| | Genistein | 2 | 2004 | 13 | 0.400 |
Why?
| | Signal Transduction | 7 | 2022 | 5226 | 0.390 |
Why?
| | Cell Proliferation | 9 | 2021 | 2496 | 0.380 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 1953 | 0.380 |
Why?
| | Enzyme Inhibitors | 3 | 2014 | 824 | 0.380 |
Why?
| | Nuclear Proteins | 2 | 2015 | 748 | 0.370 |
Why?
| | Cell Cycle | 4 | 2021 | 596 | 0.360 |
Why?
| | Repressor Proteins | 1 | 2015 | 437 | 0.360 |
Why?
| | Animals | 35 | 2025 | 38058 | 0.360 |
Why?
| | Cells, Cultured | 13 | 2015 | 4154 | 0.350 |
Why?
| | Mice | 25 | 2022 | 18339 | 0.350 |
Why?
| | Male | 52 | 2025 | 72315 | 0.350 |
Why?
| | Intermediate Filament Proteins | 1 | 2011 | 57 | 0.340 |
Why?
| | Adult Stem Cells | 1 | 2011 | 39 | 0.330 |
Why?
| | Chromones | 1 | 2010 | 42 | 0.330 |
Why?
| | Polymorphism, Single Nucleotide | 8 | 2013 | 2145 | 0.330 |
Why?
| | Neoplastic Stem Cells | 2 | 2011 | 412 | 0.320 |
Why?
| | Mice, Knockout | 8 | 2015 | 3121 | 0.320 |
Why?
| | Necrosis | 4 | 2020 | 244 | 0.310 |
Why?
| | Morpholines | 1 | 2010 | 128 | 0.310 |
Why?
| | Nerve Tissue Proteins | 2 | 2011 | 592 | 0.310 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2011 | 436 | 0.300 |
Why?
| | Gene Deletion | 3 | 2011 | 389 | 0.280 |
Why?
| | Pregnancy, Animal | 3 | 1992 | 52 | 0.270 |
Why?
| | Neoplasm Invasiveness | 4 | 2015 | 508 | 0.270 |
Why?
| | Cell Differentiation | 4 | 2014 | 2050 | 0.260 |
Why?
| | Humans | 60 | 2025 | 144759 | 0.260 |
Why?
| | Mutation, Missense | 3 | 2009 | 340 | 0.260 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2011 | 291 | 0.260 |
Why?
| | Hyperoxaluria | 2 | 2011 | 3 | 0.250 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2021 | 1455 | 0.240 |
Why?
| | Clinical Enzyme Tests | 1 | 2006 | 9 | 0.240 |
Why?
| | Prostatic Hyperplasia | 2 | 2004 | 40 | 0.240 |
Why?
| | Promoter Regions, Genetic | 4 | 2009 | 1257 | 0.240 |
Why?
| | Spectrophotometry | 1 | 2006 | 61 | 0.240 |
Why?
| | Calcifediol | 3 | 2015 | 31 | 0.240 |
Why?
| | Gene Expression Regulation | 6 | 2011 | 2608 | 0.240 |
Why?
| | PTEN Phosphohydrolase | 5 | 2019 | 164 | 0.230 |
Why?
| | Cell Lineage | 1 | 2007 | 376 | 0.230 |
Why?
| | Genotype | 7 | 2008 | 1833 | 0.220 |
Why?
| | Systems Biology | 1 | 2025 | 72 | 0.220 |
Why?
| | Pancreatic Neoplasms | 2 | 2011 | 919 | 0.210 |
Why?
| | Biomarkers, Tumor | 4 | 2019 | 1313 | 0.210 |
Why?
| | Cyclins | 1 | 2004 | 84 | 0.200 |
Why?
| | Allelic Imbalance | 1 | 2003 | 9 | 0.200 |
Why?
| | Endocrinology | 1 | 2004 | 77 | 0.200 |
Why?
| | Proteins | 4 | 1997 | 1021 | 0.200 |
Why?
| | Polymorphism, Genetic | 2 | 2003 | 612 | 0.200 |
Why?
| | Cell Cycle Proteins | 3 | 2010 | 628 | 0.190 |
Why?
| | Leukocytes, Mononuclear | 1 | 2006 | 573 | 0.190 |
Why?
| | Apoptosis | 6 | 2016 | 2430 | 0.190 |
Why?
| | Fibroblasts | 2 | 2014 | 1034 | 0.190 |
Why?
| | Tumor Cells, Cultured | 8 | 2015 | 919 | 0.190 |
Why?
| | Receptors, Somatotropin | 2 | 1992 | 10 | 0.190 |
Why?
| | Specimen Handling | 1 | 2004 | 186 | 0.190 |
Why?
| | Linkage Disequilibrium | 1 | 2003 | 246 | 0.190 |
Why?
| | Cell Communication | 1 | 2004 | 324 | 0.190 |
Why?
| | Antineoplastic Agents | 2 | 2004 | 2194 | 0.180 |
Why?
| | Parathyroid Hormone | 3 | 1997 | 112 | 0.170 |
Why?
| | Drug Synergism | 3 | 2010 | 357 | 0.170 |
Why?
| | Phenylthiohydantoin | 1 | 2021 | 44 | 0.170 |
Why?
| | Logistic Models | 2 | 2021 | 2117 | 0.160 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 2 | 2015 | 18 | 0.160 |
Why?
| | Prostatectomy | 2 | 2013 | 93 | 0.160 |
Why?
| | Mutation | 3 | 2007 | 4089 | 0.160 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2021 | 1137 | 0.160 |
Why?
| | Pyroptosis | 1 | 2020 | 5 | 0.160 |
Why?
| | Benzamides | 1 | 2021 | 224 | 0.160 |
Why?
| | Cell Line | 7 | 2012 | 2882 | 0.160 |
Why?
| | Nitriles | 1 | 2021 | 205 | 0.150 |
Why?
| | Carrier Proteins | 3 | 1992 | 737 | 0.150 |
Why?
| | Colony-Forming Units Assay | 2 | 2011 | 95 | 0.150 |
Why?
| | Immunoblotting | 3 | 2010 | 300 | 0.150 |
Why?
| | Neoplasms | 2 | 2014 | 2875 | 0.150 |
Why?
| | Fluorescent Antibody Technique | 2 | 2013 | 370 | 0.150 |
Why?
| | Molecular Sequence Data | 6 | 2009 | 2930 | 0.150 |
Why?
| | Polymerase Chain Reaction | 6 | 2009 | 1054 | 0.140 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2018 | 43 | 0.140 |
Why?
| | Point Mutation | 1 | 1999 | 243 | 0.140 |
Why?
| | Osteoblasts | 2 | 1996 | 145 | 0.140 |
Why?
| | Cellular Senescence | 2 | 2011 | 226 | 0.140 |
Why?
| | Mice, Nude | 3 | 2015 | 682 | 0.140 |
Why?
| | Genetic Markers | 2 | 2013 | 331 | 0.140 |
Why?
| | NAD | 1 | 2018 | 81 | 0.140 |
Why?
| | Meningeal Neoplasms | 1 | 2019 | 94 | 0.130 |
Why?
| | RNA, Small Interfering | 3 | 2011 | 635 | 0.130 |
Why?
| | Gene Expression | 5 | 2018 | 1490 | 0.130 |
Why?
| | Transfection | 5 | 2018 | 940 | 0.130 |
Why?
| | Regeneration | 2 | 2011 | 197 | 0.130 |
Why?
| | Flow Cytometry | 4 | 2011 | 1173 | 0.130 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2021 | 881 | 0.130 |
Why?
| | Membrane Glycoproteins | 2 | 2018 | 496 | 0.130 |
Why?
| | Base Sequence | 6 | 2009 | 2190 | 0.130 |
Why?
| | Neoplasm Grading | 2 | 2015 | 307 | 0.130 |
Why?
| | Cadherins | 2 | 2015 | 201 | 0.120 |
Why?
| | Cyclic AMP | 1 | 1996 | 209 | 0.120 |
Why?
| | Oxalates | 3 | 2011 | 11 | 0.120 |
Why?
| | Transforming Growth Factor beta2 | 2 | 2014 | 33 | 0.110 |
Why?
| | Recombination, Genetic | 2 | 2007 | 205 | 0.110 |
Why?
| | Oncolytic Viruses | 1 | 2015 | 8 | 0.110 |
Why?
| | Oncolytic Virotherapy | 1 | 2015 | 13 | 0.110 |
Why?
| | Vesiculovirus | 1 | 2015 | 17 | 0.110 |
Why?
| | Down-Regulation | 2 | 2014 | 627 | 0.110 |
Why?
| | Endotoxins | 1 | 2015 | 221 | 0.110 |
Why?
| | Receptors, Eicosanoid | 2 | 2005 | 2 | 0.110 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2015 | 156 | 0.110 |
Why?
| | Metabolism | 1 | 2014 | 44 | 0.110 |
Why?
| | Adenocarcinoma | 2 | 2019 | 928 | 0.100 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2005 | 112 | 0.100 |
Why?
| | Lipid Metabolism | 2 | 2015 | 527 | 0.100 |
Why?
| | Oxidation-Reduction | 2 | 2015 | 1087 | 0.100 |
Why?
| | Liver | 3 | 2004 | 1887 | 0.100 |
Why?
| | Random Allocation | 1 | 2014 | 363 | 0.100 |
Why?
| | Proto-Oncogenes | 1 | 2013 | 29 | 0.100 |
Why?
| | Luciferases | 2 | 2003 | 152 | 0.100 |
Why?
| | Litter Size | 1 | 1992 | 18 | 0.100 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 341 | 0.090 |
Why?
| | Silymarin | 1 | 2014 | 147 | 0.090 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2011 | 758 | 0.090 |
Why?
| | DNA Copy Number Variations | 1 | 2013 | 183 | 0.090 |
Why?
| | Hydroxyproline | 1 | 2011 | 18 | 0.090 |
Why?
| | Dietary Fats, Unsaturated | 1 | 2011 | 24 | 0.090 |
Why?
| | Electrophoresis | 1 | 2011 | 31 | 0.090 |
Why?
| | Genes, Retinoblastoma | 1 | 2011 | 8 | 0.090 |
Why?
| | Genes, p16 | 1 | 2011 | 13 | 0.090 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2011 | 98 | 0.090 |
Why?
| | Nestin | 1 | 2011 | 19 | 0.080 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2014 | 928 | 0.080 |
Why?
| | Microfluidic Analytical Techniques | 1 | 2011 | 81 | 0.080 |
Why?
| | Ribonucleosides | 1 | 2010 | 7 | 0.080 |
Why?
| | Chromatin Assembly and Disassembly | 1 | 2011 | 109 | 0.080 |
Why?
| | Oxadiazoles | 1 | 2010 | 37 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-pim-1 | 1 | 2010 | 2 | 0.080 |
Why?
| | Cell Separation | 1 | 2011 | 307 | 0.080 |
Why?
| | S-Phase Kinase-Associated Proteins | 1 | 2010 | 20 | 0.080 |
Why?
| | Organ Specificity | 1 | 2011 | 312 | 0.080 |
Why?
| | Amino Acid Sequence | 3 | 2000 | 2155 | 0.080 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2011 | 142 | 0.080 |
Why?
| | Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2010 | 19 | 0.080 |
Why?
| | Disease Progression | 2 | 2015 | 2847 | 0.080 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2015 | 905 | 0.080 |
Why?
| | Hydroxypyruvate Reductase | 2 | 2000 | 2 | 0.080 |
Why?
| | Expressed Sequence Tags | 2 | 2000 | 43 | 0.080 |
Why?
| | Glucose | 1 | 2015 | 1047 | 0.080 |
Why?
| | Parathyroid Hormone-Related Protein | 4 | 1997 | 25 | 0.080 |
Why?
| | YY1 Transcription Factor | 1 | 2009 | 25 | 0.080 |
Why?
| | Brain Neoplasms | 1 | 2019 | 1318 | 0.070 |
Why?
| | DNA, Complementary | 2 | 2000 | 276 | 0.070 |
Why?
| | Prostatic Secretory Proteins | 1 | 2009 | 4 | 0.070 |
Why?
| | Physical Chromosome Mapping | 1 | 2009 | 20 | 0.070 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 3 | 2016 | 54 | 0.070 |
Why?
| | Endothelial Cells | 1 | 2015 | 869 | 0.070 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2009 | 19 | 0.070 |
Why?
| | Sequence Homology, Amino Acid | 2 | 2000 | 396 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 5 | 2009 | 2363 | 0.070 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2010 | 380 | 0.070 |
Why?
| | Ataxins | 1 | 2007 | 5 | 0.070 |
Why?
| | Ataxin-1 | 1 | 2007 | 5 | 0.070 |
Why?
| | Hypoglycemic Agents | 2 | 2015 | 1387 | 0.070 |
Why?
| | Integrin alpha6 | 1 | 2007 | 9 | 0.070 |
Why?
| | Risk Factors | 2 | 2021 | 10779 | 0.070 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 297 | 0.070 |
Why?
| | Growth Hormone | 3 | 1992 | 92 | 0.070 |
Why?
| | RNA-Binding Proteins | 3 | 2022 | 462 | 0.070 |
Why?
| | Gene Frequency | 1 | 2009 | 481 | 0.070 |
Why?
| | Rats | 4 | 2015 | 5597 | 0.070 |
Why?
| | Statistics, Nonparametric | 1 | 2008 | 427 | 0.070 |
Why?
| | Alleles | 2 | 2008 | 879 | 0.070 |
Why?
| | Response Elements | 2 | 2009 | 89 | 0.070 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2007 | 46 | 0.070 |
Why?
| | Culture Media, Serum-Free | 2 | 2005 | 42 | 0.060 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 529 | 0.060 |
Why?
| | Cell Movement | 1 | 2012 | 965 | 0.060 |
Why?
| | Clone Cells | 1 | 2007 | 266 | 0.060 |
Why?
| | Chromosome Deletion | 1 | 2007 | 124 | 0.060 |
Why?
| | Japan | 1 | 2007 | 143 | 0.060 |
Why?
| | Hydroxyeicosatetraenoic Acids | 2 | 2005 | 35 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 983 | 0.060 |
Why?
| | Receptor-Interacting Protein Serine-Threonine Kinases | 2 | 2016 | 14 | 0.060 |
Why?
| | Carbohydrate Dehydrogenases | 1 | 2006 | 11 | 0.060 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2007 | 381 | 0.060 |
Why?
| | Blotting, Western | 2 | 2006 | 1187 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2010 | 2027 | 0.060 |
Why?
| | Middle Aged | 9 | 2013 | 35875 | 0.060 |
Why?
| | Genetic Vectors | 1 | 2007 | 337 | 0.060 |
Why?
| | DNA, Neoplasm | 2 | 2003 | 163 | 0.060 |
Why?
| | Prostatic Diseases | 1 | 2005 | 4 | 0.060 |
Why?
| | Parainfluenza Virus 5 | 1 | 2005 | 1 | 0.060 |
Why?
| | RNA, Messenger | 5 | 2011 | 2832 | 0.060 |
Why?
| | Viral Structural Proteins | 1 | 2005 | 12 | 0.060 |
Why?
| | Arachidonic Acids | 1 | 2005 | 43 | 0.060 |
Why?
| | Vesicular stomatitis Indiana virus | 1 | 2004 | 13 | 0.060 |
Why?
| | Tolonium Chloride | 1 | 2004 | 4 | 0.050 |
Why?
| | Viral Matrix Proteins | 1 | 2004 | 29 | 0.050 |
Why?
| | ADP Ribose Transferases | 1 | 2004 | 9 | 0.050 |
Why?
| | Glycolates | 1 | 2004 | 5 | 0.050 |
Why?
| | DNA Mutational Analysis | 2 | 2009 | 406 | 0.050 |
Why?
| | Glyoxylates | 1 | 2004 | 8 | 0.050 |
Why?
| | Reference Values | 1 | 2006 | 797 | 0.050 |
Why?
| | Coloring Agents | 1 | 2004 | 93 | 0.050 |
Why?
| | Calcium Channel Agonists | 1 | 2004 | 12 | 0.050 |
Why?
| | Steroid Hydroxylases | 1 | 2004 | 20 | 0.050 |
Why?
| | Interferon Type I | 1 | 2005 | 145 | 0.050 |
Why?
| | Ergocalciferols | 1 | 2003 | 14 | 0.050 |
Why?
| | Lung | 2 | 2015 | 4109 | 0.050 |
Why?
| | MicroRNAs | 1 | 2010 | 701 | 0.050 |
Why?
| | Microscopy, Fluorescence | 1 | 2005 | 416 | 0.050 |
Why?
| | Analysis of Variance | 2 | 2003 | 1306 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2013 | 2115 | 0.050 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2003 | 43 | 0.050 |
Why?
| | beta-Galactosidase | 1 | 2003 | 77 | 0.050 |
Why?
| | Palpation | 1 | 2003 | 15 | 0.050 |
Why?
| | Sequence Analysis, DNA | 2 | 2003 | 824 | 0.050 |
Why?
| | Trinucleotide Repeats | 1 | 2003 | 31 | 0.050 |
Why?
| | Adult | 6 | 2013 | 40449 | 0.050 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2004 | 162 | 0.050 |
Why?
| | Gene Amplification | 1 | 2003 | 120 | 0.050 |
Why?
| | Up-Regulation | 2 | 2004 | 851 | 0.050 |
Why?
| | Transcription, Genetic | 1 | 2009 | 1496 | 0.050 |
Why?
| | G2 Phase | 1 | 2002 | 39 | 0.050 |
Why?
| | Phosphoproteins | 1 | 2005 | 344 | 0.050 |
Why?
| | G1 Phase | 1 | 2002 | 66 | 0.050 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2002 | 66 | 0.050 |
Why?
| | Cell Culture Techniques | 1 | 2005 | 375 | 0.050 |
Why?
| | Radioimmunoassay | 2 | 1992 | 165 | 0.050 |
Why?
| | Viral Proteins | 1 | 2005 | 355 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2011 | 3409 | 0.050 |
Why?
| | Cloning, Molecular | 1 | 2003 | 540 | 0.050 |
Why?
| | Peptide Elongation Factors | 1 | 2022 | 15 | 0.050 |
Why?
| | Genes, Tumor Suppressor | 1 | 2002 | 83 | 0.050 |
Why?
| | Transforming Growth Factor beta | 1 | 2005 | 479 | 0.040 |
Why?
| | Transcription Factors | 1 | 2010 | 1741 | 0.040 |
Why?
| | Haplotypes | 1 | 2003 | 490 | 0.040 |
Why?
| | Embryo, Mammalian | 1 | 2002 | 232 | 0.040 |
Why?
| | In Vitro Techniques | 1 | 2003 | 1047 | 0.040 |
Why?
| | Vitamin D3 24-Hydroxylase | 2 | 2015 | 16 | 0.040 |
Why?
| | Kinetics | 2 | 1996 | 1627 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2002 | 310 | 0.040 |
Why?
| | Founder Effect | 1 | 2000 | 13 | 0.040 |
Why?
| | Multienzyme Complexes | 1 | 2000 | 67 | 0.040 |
Why?
| | Codon, Nonsense | 1 | 2000 | 44 | 0.040 |
Why?
| | Glyceric Acids | 1 | 2000 | 4 | 0.040 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2000 | 36 | 0.040 |
Why?
| | Aged | 6 | 2013 | 25913 | 0.040 |
Why?
| | Mixed Function Oxygenases | 1 | 2000 | 49 | 0.040 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 1999 | 26 | 0.040 |
Why?
| | Consensus Sequence | 1 | 1999 | 74 | 0.040 |
Why?
| | Gene Knockdown Techniques | 2 | 2011 | 336 | 0.040 |
Why?
| | Microsatellite Repeats | 1 | 2000 | 157 | 0.040 |
Why?
| | Chemoprevention | 1 | 2000 | 90 | 0.040 |
Why?
| | Trans-Activators | 1 | 2022 | 405 | 0.040 |
Why?
| | COS Cells | 1 | 1999 | 181 | 0.040 |
Why?
| | Genes | 1 | 1999 | 226 | 0.040 |
Why?
| | Codon | 1 | 1999 | 94 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2000 | 327 | 0.040 |
Why?
| | Parenchymal Tissue | 1 | 2019 | 4 | 0.040 |
Why?
| | Green Fluorescent Proteins | 2 | 2015 | 405 | 0.040 |
Why?
| | Transcriptional Regulator ERG | 1 | 2019 | 14 | 0.040 |
Why?
| | Cell Death | 2 | 2015 | 383 | 0.040 |
Why?
| | Sequence Alignment | 1 | 1999 | 366 | 0.040 |
Why?
| | Time Factors | 4 | 2009 | 7173 | 0.040 |
Why?
| | Nicotinamide Phosphoribosyltransferase | 1 | 2018 | 8 | 0.040 |
Why?
| | Sweden | 2 | 2009 | 111 | 0.040 |
Why?
| | Transaminases | 2 | 2011 | 22 | 0.040 |
Why?
| | Phenotype | 1 | 2007 | 3162 | 0.040 |
Why?
| | Exons | 1 | 1999 | 358 | 0.030 |
Why?
| | Species Specificity | 1 | 1999 | 574 | 0.030 |
Why?
| | Serine Endopeptidases | 1 | 2019 | 128 | 0.030 |
Why?
| | Acrylamides | 1 | 2018 | 70 | 0.030 |
Why?
| | Cellular Reprogramming | 1 | 2018 | 103 | 0.030 |
Why?
| | Tretinoin | 1 | 2018 | 124 | 0.030 |
Why?
| | Recombinant Proteins | 2 | 2015 | 1370 | 0.030 |
Why?
| | Piperidines | 1 | 2018 | 217 | 0.030 |
Why?
| | Receptors, Death Domain | 1 | 2016 | 4 | 0.030 |
Why?
| | Autophagy-Related Protein 5 | 1 | 2016 | 8 | 0.030 |
Why?
| | Autophagosomes | 1 | 2016 | 20 | 0.030 |
Why?
| | Protein Kinases | 1 | 2018 | 315 | 0.030 |
Why?
| | Mitochondria | 2 | 2018 | 984 | 0.030 |
Why?
| | Biomarkers | 1 | 2007 | 4271 | 0.030 |
Why?
| | Prevalence | 1 | 2003 | 2834 | 0.030 |
Why?
| | Culture Media | 1 | 1996 | 161 | 0.030 |
Why?
| | Epidermal Growth Factor | 1 | 1996 | 171 | 0.030 |
Why?
| | Cell Survival | 2 | 2011 | 1098 | 0.030 |
Why?
| | Epithelium | 1 | 1996 | 314 | 0.030 |
Why?
| | Fatty Acids | 1 | 2018 | 450 | 0.030 |
Why?
| | Genes, Viral | 1 | 2015 | 90 | 0.030 |
Why?
| | Pregnancy | 3 | 1992 | 7190 | 0.030 |
Why?
| | Heterografts | 1 | 2015 | 143 | 0.030 |
Why?
| | STAT1 Transcription Factor | 1 | 2015 | 68 | 0.030 |
Why?
| | Poly(ADP-ribose) Polymerases | 2 | 2005 | 86 | 0.030 |
Why?
| | Pertussis Toxin | 2 | 2005 | 24 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2005 | 4557 | 0.030 |
Why?
| | Caspases | 2 | 2005 | 232 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 323 | 0.030 |
Why?
| | Case-Control Studies | 3 | 2009 | 3604 | 0.020 |
Why?
| | Lipids | 1 | 2018 | 710 | 0.020 |
Why?
| | Placental Lactogen | 1 | 1992 | 17 | 0.020 |
Why?
| | Female | 5 | 2006 | 78271 | 0.020 |
Why?
| | Sheep | 1 | 2015 | 880 | 0.020 |
Why?
| | Phosphorylation | 2 | 2010 | 1732 | 0.020 |
Why?
| | Blotting, Northern | 1 | 1992 | 204 | 0.020 |
Why?
| | Microsomes, Liver | 1 | 1992 | 85 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 1996 | 1716 | 0.020 |
Why?
| | Nephrocalcinosis | 1 | 2011 | 13 | 0.020 |
Why?
| | Models, Biological | 1 | 2000 | 1821 | 0.020 |
Why?
| | Binding, Competitive | 1 | 1992 | 193 | 0.020 |
Why?
| | Animal Feed | 1 | 2011 | 53 | 0.020 |
Why?
| | Protein Binding | 2 | 2010 | 2273 | 0.020 |
Why?
| | Transcriptome | 1 | 2018 | 1045 | 0.020 |
Why?
| | Orchiectomy | 1 | 2011 | 74 | 0.020 |
Why?
| | Fatty Acid Desaturases | 1 | 2011 | 31 | 0.020 |
Why?
| | Fatty Acids, Omega-6 | 1 | 2011 | 48 | 0.020 |
Why?
| | Gene Knockout Techniques | 1 | 2011 | 116 | 0.020 |
Why?
| | Homozygote | 1 | 2011 | 199 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2011 | 193 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2011 | 251 | 0.020 |
Why?
| | Sensitivity and Specificity | 2 | 2009 | 1985 | 0.020 |
Why?
| | Proteolysis | 1 | 2011 | 173 | 0.020 |
Why?
| | Spheroids, Cellular | 1 | 2011 | 73 | 0.020 |
Why?
| | Peptide Fragments | 1 | 1995 | 699 | 0.020 |
Why?
| | Apc3 Subunit, Anaphase-Promoting Complex-Cyclosome | 1 | 2010 | 1 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2011 | 159 | 0.020 |
Why?
| | Rabbits | 1 | 1992 | 648 | 0.020 |
Why?
| | Cytokines | 1 | 2018 | 2061 | 0.020 |
Why?
| | Odds Ratio | 1 | 2013 | 1075 | 0.020 |
Why?
| | S Phase | 1 | 2010 | 80 | 0.020 |
Why?
| | Antioxidants | 1 | 2014 | 549 | 0.020 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2015 | 410 | 0.020 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 1 | 2010 | 56 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2011 | 286 | 0.020 |
Why?
| | Ubiquitination | 1 | 2010 | 118 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 331 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2015 | 2527 | 0.020 |
Why?
| | Pulmonary Artery | 1 | 2015 | 1134 | 0.020 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2010 | 81 | 0.020 |
Why?
| | HEK293 Cells | 1 | 2011 | 744 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2013 | 1462 | 0.020 |
Why?
| | HeLa Cells | 1 | 2010 | 650 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2009 | 766 | 0.020 |
Why?
| | Antigens, CD | 1 | 2010 | 555 | 0.020 |
Why?
| | Computer Simulation | 1 | 2011 | 1025 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2011 | 2182 | 0.020 |
Why?
| | Placenta | 1 | 1992 | 780 | 0.010 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 1 | 2005 | 17 | 0.010 |
Why?
| | Prostaglandin D2 | 1 | 2005 | 22 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2009 | 1539 | 0.010 |
Why?
| | Fas-Associated Death Domain Protein | 1 | 2005 | 9 | 0.010 |
Why?
| | Anilides | 1 | 2005 | 84 | 0.010 |
Why?
| | ADP-Ribosylation Factors | 1 | 2005 | 18 | 0.010 |
Why?
| | Caspase 8 | 1 | 2005 | 47 | 0.010 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2005 | 53 | 0.010 |
Why?
| | DNA Fragmentation | 1 | 2004 | 39 | 0.010 |
Why?
| | Retinoblastoma Protein | 1 | 2005 | 61 | 0.010 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2005 | 73 | 0.010 |
Why?
| | Peroxisomes | 1 | 2004 | 11 | 0.010 |
Why?
| | Caspase 3 | 1 | 2005 | 238 | 0.010 |
Why?
| | PPAR gamma | 1 | 2005 | 176 | 0.010 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2004 | 115 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 2005 | 415 | 0.010 |
Why?
| | Prognosis | 1 | 2013 | 4282 | 0.010 |
Why?
| | Mitosis | 1 | 2005 | 200 | 0.010 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2005 | 186 | 0.010 |
Why?
| | Adenoviridae | 1 | 2005 | 199 | 0.010 |
Why?
| | Diet | 1 | 2011 | 1273 | 0.010 |
Why?
| | Models, Molecular | 1 | 2009 | 1618 | 0.010 |
Why?
| | Radiation, Ionizing | 1 | 2003 | 87 | 0.010 |
Why?
| | Chlorobenzenes | 1 | 2002 | 19 | 0.010 |
Why?
| | Phagocytosis | 1 | 2005 | 299 | 0.010 |
Why?
| | Stimulation, Chemical | 1 | 2002 | 53 | 0.010 |
Why?
| | Carcinoma | 1 | 2005 | 228 | 0.010 |
Why?
| | DNA Primers | 1 | 2004 | 512 | 0.010 |
Why?
| | Benzoquinones | 1 | 2002 | 47 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2005 | 862 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2002 | 138 | 0.010 |
Why?
| | Cattle | 1 | 2005 | 1000 | 0.010 |
Why?
| | GTP-Binding Proteins | 1 | 2002 | 153 | 0.010 |
Why?
| | Binding Sites | 1 | 2005 | 1329 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2002 | 175 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2004 | 1253 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2005 | 427 | 0.010 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2005 | 459 | 0.010 |
Why?
| | Virus Replication | 1 | 2004 | 529 | 0.010 |
Why?
| | Probability | 1 | 2002 | 310 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2002 | 292 | 0.010 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2005 | 529 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2019 | 17066 | 0.010 |
Why?
| | Inflammation | 1 | 2011 | 2878 | 0.010 |
Why?
| | Registries | 1 | 2009 | 2385 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2005 | 1217 | 0.010 |
Why?
| | Proto-Oncogene Proteins | 1 | 2002 | 623 | 0.010 |
Why?
| | Genetic Variation | 1 | 2004 | 983 | 0.010 |
Why?
| | Indoles | 1 | 2002 | 501 | 0.010 |
Why?
| | Cell Count | 1 | 1997 | 320 | 0.010 |
Why?
| | Phorbol Esters | 1 | 1995 | 13 | 0.010 |
Why?
| | Teriparatide | 1 | 1995 | 10 | 0.010 |
Why?
| | Colforsin | 1 | 1995 | 48 | 0.010 |
Why?
| | Second Messenger Systems | 1 | 1995 | 31 | 0.010 |
Why?
| | Osteosarcoma | 1 | 1995 | 76 | 0.010 |
Why?
| | Brain | 1 | 2004 | 2933 | 0.010 |
Why?
| | Cohort Studies | 1 | 2002 | 5960 | 0.010 |
Why?
| | Prospective Studies | 1 | 2002 | 7990 | 0.000 |
Why?
| | Aged, 80 and over | 1 | 2002 | 8265 | 0.000 |
Why?
|
|
Cramer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|